API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Leap intends to use the net proceeds from the financing to fund the continued development of its lead monoclonal antibody program, DKN-01 for the treatment of Colorectal Cancer.
Lead Product(s): Sirexatamab,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 11, 2024
Details:
Ipsen acquired exclusive commercialization rights for the current and potential future Onivyde, a unique encapsulation formulation of irinotecan in a long-circulating liposomal, as a first-line treatment of metastatic adenocarcinoma on the pancreas in the US.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: $1,025.0 million Upfront Cash: $575.0 million
Deal Type: Acquisition March 27, 2024
Details:
AbilityPharma to obtain financing for the clinical development of ABTL0812 in combination with folfirinox. It is being evaluated in Phase I/II clinical trial studies for the treatment of Metastatic Pancreatic Cancer.
Lead Product(s): ABTL0812,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: ABTL0812
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CTI Life Sciences
Deal Size: $7.6 million Upfront Cash: Undisclosed
Deal Type: Financing March 11, 2024
Details:
Oncotelic lead product candidate, OT-101 is a TGF beta-2 inhibitor in combination with folfirinox. It is currently being evaluated in the Phase 2/3 clinical trial studies with patients for the treatment of Pancreatic Ductal Adenocarcinoma.
Lead Product(s): OT-101,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
Onivyde (irinotecan), liposomal injection is a small molecule drug that blocks an enzyme called topoisomerase I. It is being developed for the treatment of metastatic pancreatic adenocarcinoma.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.
Lead Product(s): AMP945,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: AMP945
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
CV6-168 is a first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase.
Lead Product(s): CV6-168,Fluorouracil
Therapeutic Area: Oncology Product Name: CV6-168
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
Keytruda (pembrolizumab)- a monoclonal anti-PD-1 therapy in combination with fluoropyrimidine- & platinum-containing chemotherapy is approved for the treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GDJ adenocarcinoma.
Lead Product(s): Pembrolizumab,Cisplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
Under the terms of the agreement, Henlius will be responsible for clinical development, manufacturing and supply upon launch of specific formulation of HANSIZHUANG (serplulimab injection), Henlius' novel anti-PD-1 mAb.
Lead Product(s): Serplulimab,Fluorouracil
Therapeutic Area: Oncology Product Name: Hansizhuang
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Intas Pharmaceuticals
Deal Size: $195.5 million Upfront Cash: $44.4 million
Deal Type: Collaboration October 27, 2023
Details:
Imfinzi (durvalumab) is a PD-L1 Inhibitor antibody drug candidate, which is currently being evaluated in combination with fluorouracil & leucovorin for the treatment of resectable gastric and gastroesophageal junction cancer.
Lead Product(s): Durvalumab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
Hansizhuang (serplulimab) is a novel humanized monoclonal anti-PD-1 antibody, which is approved for the first-line treatment of extensive stage small cell lung cancer in combination with fluorouracil and etoposide.
Lead Product(s): Serplulimab,Fluorouracil
Therapeutic Area: Oncology Product Name: Hansizhuang
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2023
Details:
OT-101, is a first-in-class anti-TGF-β2 RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer (metastatic pancreatic cancer) patients. TGF-β2 has been implicated as a key contributor to the immunosuppressive landscape of the TME in HGG.
Lead Product(s): Trabedersen,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cromos Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
Under the Agreement, Allarity will support FivepHusion’s future clinical development of Deflexifol (5-fluorouracil) for the treatment of solid tumors by using certain of Allarity’s drug-specific DRP® companion diagnostics, including its validated DRP®-5FU companion diagnostic.
Lead Product(s): Fluorouracil,Calcium Folinate,Oxaliplatin
Therapeutic Area: Oncology Product Name: Deflexifol
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Allarity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 31, 2023
Details:
IMAB362 (zolbetuximab) is an investigational, first-in-class chimeric IgG1 mAb that targets and binds to CLDN18.2 present on the cancer cell surface of gastric epithelial cells. It induces cancer cell death by activating ADCC and CDC immune system.
Lead Product(s): Zolbetuximab,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: IMAB362
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Details:
The company intends to use the net proceeds for its pipeline development including, IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) that is being developed for the treatment of patients with solid and hematologic malignancies.
Lead Product(s): IGM-8444,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: IGM-8444
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 22, 2023
Details:
Keytruda (pembrolizumab) is a humanized mAb, anti-PD-1 therapy that blocks the interaction between PD-1 and its ligands, with chemotherapy, thereby activating T lymphocytes which may affect tumor cells in patients with Advanced Resectable Gastric cancer.
Lead Product(s): Pembrolizumab,Cisplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
Onivyde (irinotecan) is a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. By blocking the enzyme, which is investigated for treatment of pancreatic ductal adenocarcinoma.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
IGM-8444 is an IgM antibody targeting death receptor 5 (DR5) that is being developed for the treatment of patients with solid tumor including metastatic colorectal cancerand hematologic malignancies.
Lead Product(s): IGM-8444,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: IGM-8444
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2023
Details:
AMP945 (narmafotinib) is an orally bioavailable small molecule with a best-in-class profile. Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer.
Lead Product(s): AMP945,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: AMP945
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2023
Details:
The collaboration is for strategically and optimally progress development and commercialization of FivepHusion's enhanced chemotherapeutic formulation Deflexifol, an anti-cancer drug reformulation combining 5-fluorouracil and its biomodulator leucovorin, in global markets.
Lead Product(s): Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Deflexifol
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Syneos Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 26, 2023
Details:
Keytruda® (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Lead Product(s): Pembrolizumab,Cisplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
Fluorouracil is a nucleoside metabolic inhibitor that interferes with the synthesis of DNA and to a lesser extent inhibits the formation of RNA, these affect rapidly growing cells and may lead to cell death.
Lead Product(s): Fluorouracil
Therapeutic Area: Oncology Product Name: Fluorouracil-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
Cosela (Trilaciclib) is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.
Lead Product(s): Trilaciclib,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Onivyde (irinotecan) is a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. By blocking the enzyme, cancer cells are prevented from multiplying and eventually die.
Lead Product(s): Irinotecan Hydrochloride,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
BGB-A317 (tislelizumab) is a humanized IgG4 anti-PD-1 monoclonal antibody designed to minimize binding of Fcγ receptors on macrophages, helping body’s immune cells to detect and fight tumors. It is being evaluated in solid tumor and hematologic malignancies.
Lead Product(s): Tislelizumab,Cisplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BGB-A317
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) that is being developed for the treatment of patients with solid and hematologic malignancies.
Lead Product(s): IGM-8444,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: IGM-8444
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Cejemly (sugemalimab) is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody, being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma.
Lead Product(s): Sugemalimab,Fluorouracil,Cisplatin
Therapeutic Area: Oncology Product Name: Cejemly
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
ADC-1013 (Mitazalimab) is an agonistic/stimulatory antibody that targets and activates CD40 (receptor on the dendritic cells of the immune system), enabling dendritic cells to stimulate the immune response’s weapons more effectively to attack the cancer selectively.
Lead Product(s): Mitazalimab,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2023
Details:
In AGENT study, patients with non-resectable mCRC treated with arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab did not achieve a statistically significant overall response rate of ≥ 10% as compared to patients treated with the standard of care.
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Modufolin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 25, 2022
Details:
KEYTRUDA® (pembrolizumab) injection, 100 mg, is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells.
Lead Product(s): Pembrolizumab,Cisplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that alters the unfolded protein response (UPR) through selective GRP78 inhibition and induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest.
Lead Product(s): Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
The antibody CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. It can counteract contribution of IL-1 system to immune suppressive tumor microenvironment and development of resistance to chemotherapy.
Lead Product(s): Nadunolimab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
Progression-free survival (PFS) was approximately 12.8 months for the arfolitixorin arm and 11.6 months for the control arm, with a P-value of 0.76. Data for this endpoint is not final but it is not deemed to change significantly moving forward.
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Modufolin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
CYAD-101 is an investigational, non-gene edited allogeneic CAR T engineered to co-express chimeric antigen receptor based on NKG2D, that binds to eight stress-induced ligands expressed by a broad range of tumor cells and the novel inhibitory peptide TIM.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
First-line BGB-A317 (tislelizumab) plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal squamous cell carcinoma.
Lead Product(s): Tislelizumab,Cisplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BGB-A317
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition.
Lead Product(s): Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
The results of trial showed that mFOLFOX6 + Vectibix (Panitumumab) combination provides a statistically significant improvement in OS over mFOLFOX6 + bevacizumab combination in patients with a left-sided primary tumor or regardless of tumor locations.
Lead Product(s): Panitumumab,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: Vectibix
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
The study achieved its primary endpoint that demonstrated a significant correlation between DetermaIO and two-year overall survival in atezolizumab treated metastatic bladder cancer.
Lead Product(s): Atezolizumab,Bevacizumab,Fluorouracil
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Arfox
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
Ampligen (rintatolimod) has demonstrated in clinic potential for standalone efficacy in a number of solid tumors, it also has shown success in increasing survival rates and efficacy in treatment of animal tumors when used in combination with checkpoint blockade therapies.
Lead Product(s): Rintatolimod,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
Results showed Reolysin (pelareorep) treatment led to the activation of NK cells, in patient samples and in vitro, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity.
Lead Product(s): Pelareorep,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
Company announced clinical hold on CYAD-101-002 Phase 1b trial for CYAD-101, TCR Inhibitory Molecule based allogeneic NKG2D CAR T cell investigational therapy for treatment of advanced mCRC, due to insufficient information to assess risk to study subjects.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
The trial is evaluating TCR Inhibitory Molecule-based allogeneic NKG2D CAR T cell investigational therapy CYAD-101 administered concurrently with FOLFOX chemotherapy, followed by MSD’s anti-PD-1 therapy, KEYTRUDA®, in patients with refractory metastatic colorectal cancer.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
The positive opinion is based on results from the Phase 3 CheckMate -648 trial, which showed that treatment with Opdivo plus chemotherapy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to chemotherapy alone.
Lead Product(s): Nivolumab,Cisplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2022
Details:
The sponsored research collaboration will support the UPENN study, a part of Alligator’s OPTIMIZE-1 clinical trial, multi-center phase 1B/I I trial assessing the clinical efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic cancer.
Lead Product(s): Mitazalimab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Pennsylvania
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 19, 2022
Details:
ADC-1013 (mitazalimab), a CD40 agonist reported no adverse event at dosed of 450 µg/kg cohort in combination with mFOLFIRINOX for treatment of pancreatic ductal adenocarcinoma in OPTIMIZE-1 Phase Ib/II trial.
Lead Product(s): Mitazalimab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2022
Details:
Preclinical experiments have repeatedly shown that BOLD-100 improves outcomes in combination with a wide range of existing anti-cancer therapies, with particular synergy evident in drug-resistant cell lines.
Lead Product(s): BOLD-100,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hana Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 13, 2022
Details:
HERIZON-GEA-01 is Phase 3 clinical trial designed to evaluate efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy CAPOX (capecitabine/oxaliplatin) or other treatments.
Lead Product(s): Zanidatamab,Cisplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: $430.0 million Upfront Cash: $40.0 million
Deal Type: Expanded Collaboration December 08, 2021
Details:
The Company intends to use net proceeds from the private placement to fund research and development expenses, including the clinical development of its allogeneic CAR T candidates CYAD-101 and CYAD-211, to advance the current pipeline of preclinical CAR T candidates.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fortress Investment Group
Deal Size: $32.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 03, 2021
Details:
Arfox (Arfolitixorin), is the first and only immediately active folate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer.
Lead Product(s): Arfolitixorin,Fluorouracil,Oxaliplatin
Therapeutic Area: Oncology Product Name: Arfox
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2021